Goßrau Gudrun, Förderreuther Stefanie, Ruscheweyh Ruth, Ruschil Victoria, Sprenger Till, Lewis David, Kamm Katharina, Freilinger Tobias, Neeb Lars, Malzacher Volker, Meier Uwe, Gehring Klaus, Kraya Torsten, Dresler Thomas, Schankin Christoph J, Gantenbein Andreas R, Brössner Gregor, Zebenholzer Karin, Diener Hans-Christoph, Gaul Charly, Jürgens Tim P
Kopfschmerzambulanz, Universitätsschmerzcentrum, Medizinische Fakultät der TU Dresden, Universitätsklinikum Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland.
Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, München, Deutschland.
Nervenarzt. 2023 Apr;94(4):306-317. doi: 10.1007/s00115-022-01403-1. Epub 2022 Oct 26.
Migraine is the most common neurological disorder and can be associated with a high degree of disability. In addition to non-pharmacological approaches to reduce migraine frequency, pharmacological migraine preventatives are available. Evidence-based guidelines from the German Migraine and Headache Society (DMKG), and German Society for Neurology (DGN), Austrian Headache Society (ÖKSG), and Swiss Headache Society (SKG) are available for indication and application. For therapy-relevant questions such as the duration of a pharmacological migraine prevention, no conclusions can be drawn from currently available study data. The aim of this review is to present a therapy consensus statement that integrates the current data situation and, where data are lacking, expert opinions. The resulting current recommendations on the duration of therapy for pharmacological migraine prophylaxis are shown here.
偏头痛是最常见的神经系统疾病，可能导致高度残疾。除了采用非药物方法来降低偏头痛发作频率外，也有偏头痛的药物预防性治疗方法。德国偏头痛与头痛协会（DMKG）、德国神经病学学会（DGN）、奥地利头痛协会（ÖKSG）和瑞士头痛协会（SKG）发布了关于适应证和应用的循证指南。对于诸如药物性偏头痛预防疗程等与治疗相关的问题，目前可得的研究数据无法得出结论。本综述的目的是提出一份治疗共识声明，该声明整合了当前的数据情况，并在缺乏数据时纳入专家意见。以下展示了由此得出的关于药物性偏头痛预防治疗疗程的当前建议。
